| scholarly article | Q13442814 |
| P50 | author | Joo-Youn Cho | Q86428159 |
| P2093 | author name string | Sang-Heon Cho | |
| Tae-Eun Kim | |||
| Kyoung Soo Lim | |||
| Kyung-Sang Yu | |||
| Seo Hyun Yoon | |||
| Namyi Gu | |||
| In-Jin Jang | |||
| Mi Young Bahng | |||
| Min Kyu Park | |||
| P2860 | cites work | Standards of medical care in diabetes--2013 | Q29620309 |
| Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits | Q33602360 | ||
| Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors | Q34374336 | ||
| Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes | Q34648201 | ||
| Diurnal pattern to insulin secretion and insulin action in healthy individuals | Q36339611 | ||
| The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
| Pharmacokinetics of dipeptidylpeptidase-4 inhibitors | Q37768821 | ||
| DPP-4 inhibitors: what may be the clinical differentiators? | Q37779906 | ||
| Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. | Q37910902 | ||
| Incretin effect: GLP-1, GIP, DPP4. | Q37921901 | ||
| A review of gliptins in 2011. | Q37965612 | ||
| Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. | Q37979374 | ||
| Clinical pharmacokinetics and pharmacodynamics of vildagliptin | Q37984567 | ||
| Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study | Q38464759 | ||
| Pharmacokinetic study of saxagliptin in healthy Chinese subjects | Q38470357 | ||
| Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage | Q40035788 | ||
| Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. | Q40667988 | ||
| Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. | Q42164402 | ||
| A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis | Q42480141 | ||
| A diabetes report card for the United States: quality of care in the 1990s | Q43960347 | ||
| Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects | Q44686546 | ||
| Diurnal variation in blood sugar and serum insulin in response to glucose and/or glucagon in healthy subjects | Q51671377 | ||
| DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. | Q51764065 | ||
| The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity | Q58448710 | ||
| Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm | Q68098718 | ||
| [GLP-1 (7-36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM] | Q77416575 | ||
| Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes | Q84097974 | ||
| The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study | Q84357802 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 1709-1721 | |
| P577 | publication date | 2014-10-06 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers | |
| P478 | volume | 8 |
| Q38644587 | Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. |
| Q38922177 | DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control |
| Q38625769 | Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers |
| Q51373715 | Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). |
| Q33626226 | Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension |
| Q92341046 | Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study |
| Q47185104 | Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise |
| Q34500716 | Evogliptin: First Global Approval |
| Q38828606 | Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes |
| Q53236559 | In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations. |
| Q37179450 | Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. |
| Q36808160 | Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects |
| Q91795502 | Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor |
Search more.